<a href="https://laohu8.com/S/LFST">LifeStance Health</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> Revenue Growth of 11% to $345.<a href="https://laohu8.com/S/MMM">3M</a>, Net Loss Narrows to $3.8M, Adjusted EBITDA Rises 19% to $34M
LifeStance Health Group Inc. reported a net loss of $3.8 million, a significant improvement from the net loss of $23.3 million in the previous period. In the second quarter, the company achieved net cash provided by operations amounting to $64.4 million and a free cash flow of positive $56.6 million. Adjusted EBITDA increased by 19%, reaching $34.0 million, compared to $28.6 million previously. For the full year 2025, LifeStance reiterated its revenue expectations of $1.40 billion to $1.44 billion. The company raised its Center Margin expectations to $441 million to $465 million and increased its Adjusted EBITDA expectations to a range of $140 million to $150 million. CEO Dave Bourdon highlighted the addition of over 170 clinicians and improved productivity, contributing to double-digit organic revenue growth and 10% Adjusted EBITDA margins.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeStance Health Group Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。